You are here
PreludeDx to Present Results from PREDICT Study at ASBrS Annual Meeting
LAGUNA HILLS, Calif., May 1, 2019 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, will present interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled "Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS", at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Dallas, TX. The presentation will occur on Friday, May 3rd, from 6:00 – 7:30 pm CDT. PreludeDx will be exhibiting at this year's ASBrS (booth #120) during exhibit hours Thursday, May 2nd, through Saturday, May 4th.
The PREDICT study evaluates the impact of DCISionRT—the only predictive and prognostic DCIS test—on clinical management of patients with ductal carcinoma in situ (DCIS) as compared to traditional clinical and pathologic risk factors. The study will enroll up to 2,500 patients at 100 sites to demonstrate the impact DCISionRT has on DCIS treatment. The study includes large health systems and many of the nation's top cancer centers. Once completed, it will be the largest clinical utility study performed for DCIS patients. The planned interim analysis of the PREDICT study will include approximately 200 DCIS patients and is expected to have widespread implications for the way DCIS is treated in the future. PreludeDx Chief Scientific Officer, Dr. Troy Bremer, will present interim PREDICT results and will be joined by the lead investigators from 6:00 – 7:30pm CDT on Friday, May 3rd.
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. In the US, over 60,000 women are newly diagnosed with DCIS each year. The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a woman's individual tumor biology along with other risk factors to provide a personalized recurrence risk. The test provides a Decision ScoreTM that identifies a woman's risk as low or elevated. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.
PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your RiskTM.
For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk, Know Her Risk, and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidies in the United States and foreign countries.
View original content to download multimedia:http://www.prnewswire.com/news-releases/preludedx-to-present-results-from-predict-study-at-asbrs-annual-meeting-300841774.html
SOURCE Prelude Corporation